Target Price | $43.71 |
Price | $9.74 |
Potential |
348.81%
register free of charge
|
Number of Estimates | 7 |
7 Analysts have issued a price target Capricor Therapeutics, Inc. 2026 .
The average Capricor Therapeutics, Inc. target price is $43.71.
This is
348.81%
register free of charge
$77.00
690.55%
register free of charge
$25.00
156.67%
register free of charge
|
|
A rating was issued by 7 analysts: 7 Analysts recommend Capricor Therapeutics, Inc. to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Capricor Therapeutics, Inc. stock has an average upside potential 2026 of
348.81%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 22.27 | 71.26 |
11.56% | 219.97% | |
EBITDA Margin | -184.73% | 8.84% |
102.15% | 104.79% | |
Net Margin | -235.37% | -19.45% |
56.66% | 91.74% |
6 Analysts have issued a sales forecast Capricor Therapeutics, Inc. 2025 . The average Capricor Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Capricor Therapeutics, Inc. 2025 . The average Capricor Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Capricor Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Capricor Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.15 | -0.30 |
38.55% | 73.91% | |
P/E | negative | |
EV/Sales | 4.18 |
5 Analysts have issued a Capricor Therapeutics, Inc. forecast for earnings per share. The average Capricor Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Capricor Therapeutics, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 17 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 04 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 02 2025 |
Jones Trading |
Locked
➜
Locked
|
Locked | Nov 18 2024 |
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Nov 14 2024 |
Analyst Rating | Date |
---|---|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Mar 20 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 20 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 17 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 04 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 02 2025 |
Locked
Jones Trading:
Locked
➜
Locked
|
Nov 18 2024 |
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Nov 14 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.